E40 Endoprotease

About Nemysis

Nemysis is a private, pre-revenue biotech founded in 2016, developing microbiome-friendly nutritional therapeutics. Its lead programs include IHAT, a novel nano-particulate iron supplement designed to mimic natural absorption, and E40, an endoprotease for degrading immunogenic gluten peptides. The company has attracted strategic investments from European pharmaceutical firms and is advancing its pipeline through academic collaborations, targeting significant unmet needs in iron deficiency and celiac disease management.

Therapeutic Areas